Low-grade early-stage endometroid cancer (EC) is the most frequently diagnosed tumor type of the uterine corpus. Our study aimed to assess dysregulated pathways in this specific subset of tumors through proteomic analysis. There is still a knowledge gap in the molecular pathways that determine the biological behaviour of these tumors. The purpose of this study was to describe dysregulated molecular pathways from EC patients. Paired healthy controls were collected and both subjected to MS/MS proteomic analysis.